SI2442651T1 - Zdravljenje multiple skleroze z lakvinimodom - Google Patents

Zdravljenje multiple skleroze z lakvinimodom

Info

Publication number: SI2442651T1
Authority: SI; Slovenia
Prior art keywords: laquinimod; treatment; multiple sclerosis; sclerosis
Prior art date: 2009-06-19

Application number

SI201031018T

Other languages

English (en)

Inventor

Nora Tarcic

Dan Bar-Zohar

Dina Kofler

Original Assignee

Teva Pharmaceutical Industries Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-19

Filing date

2010-06-18

Publication date

2015-10-30

2010-06-18 Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.

2015-10-30 Publication of SI2442651T1 publication Critical patent/SI2442651T1/sl

Links

GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
229960004577 laquinimod Drugs 0.000 title 1
201000006417 multiple sclerosis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Microbiology (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Plural Heterocyclic Compounds (AREA)

SI201031018T 2009-06-19 2010-06-18 Zdravljenje multiple skleroze z lakvinimodom SI2442651T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26907009P	2009-06-19	2009-06-19
EP10789873.6A EP2442651B1 (en)	2009-06-19	2010-06-18	Treatment of multiple sclerosis with laquinimod
PCT/US2010/001759 WO2010147665A1 (en)	2009-06-19	2010-06-18	Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number	Publication Date
SI2442651T1 true SI2442651T1 (sl)	2015-10-30

Family

ID=43354572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201031018T SI2442651T1 (sl)	2009-06-19	2010-06-18	Zdravljenje multiple skleroze z lakvinimodom

Country Status (26)

Country	Link
US (7)	US20100322900A1 (sl)
EP (2)	EP3028572A1 (sl)
JP (4)	JP2012530701A (sl)
KR (2)	KR20120037477A (sl)
CN (2)	CN107308162A (sl)
AU (2)	AU2010260455A1 (sl)
BR (1)	BR112012000568A2 (sl)
CY (1)	CY1116727T1 (sl)
DK (1)	DK2442651T3 (sl)
EA (1)	EA201270041A1 (sl)
ES (1)	ES2548999T3 (sl)
HK (1)	HK1169563A1 (sl)
HR (1)	HRP20150988T1 (sl)
HU (1)	HUE026406T2 (sl)
IL (2)	IL216780A0 (sl)
ME (1)	ME02282B (sl)
MX (1)	MX2011013902A (sl)
NZ (1)	NZ597378A (sl)
PL (1)	PL2442651T3 (sl)
PT (1)	PT2442651E (sl)
RS (1)	RS54328B1 (sl)
SG (2)	SG10201403397TA (sl)
SI (1)	SI2442651T1 (sl)
SM (1)	SMT201500262B (sl)
WO (1)	WO2010147665A1 (sl)
ZA (1)	ZA201200029B (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2843209B2 (ja) *	1992-07-28	1999-01-06	株式会社クボタ	苗詰め装置
RS53666B1 (en) *	2005-10-19	2015-04-30	Teva Pharmaceutical Industries Ltd	CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
DK2035001T3 (da)	2006-06-12	2012-02-27	Teva Pharma	Stabile laquinimod-tilberedninger
SI2234485T1 (sl)	2007-12-20	2014-03-31	Teva Pharmaceutical Industries Ltd.	Stabilni lakvinimodni pripravki
WO2010028015A2 (en) *	2008-09-03	2010-03-11	Auspex Pharmaceuticals, Inc	2-oxo-1,2-dihydro-quinoline modulators of immune function
AU2010282948C1 (en)	2009-08-10	2017-03-02	Active Biotech, Ab	Treatment of BDNF-related disorders using laquinimod
ES2601819T3 (es) *	2010-03-03	2017-02-16	Teva Pharmaceutical Industries Ltd.	Tratamiento de la artritis lúpica usando laquinimod
MX337614B (es) *	2010-03-03	2016-03-10	Teva Pharma	Tratamiento de lupus nefritis usando laquinimod.
SG183513A1 (en) *	2010-03-03	2012-09-27	Teva Pharma	Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CN102984939A (zh)	2010-07-09	2013-03-20	泰华制药工业有限公司	氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
KR20130124518A (ko) *	2010-12-07	2013-11-14	테바 파마슈티컬 인더스트리즈 리미티드	다발경화증 환자의 피로를 감소시키고, 기능 상태를 개선시키고, 삶의 질을 개선시키기 위한 라퀴니모드의 용도
EP2736336A4 (en) *	2011-07-28	2015-03-04	Teva Pharma	TREATMENT OF MULTIPLE SCLEROSIS WITH A COMBINATION OF LAQUINIMOD AND INTERFERON-BETA
EA201490377A1 (ru) *	2011-07-28	2014-11-28	Тева Фармасьютикал Индастриз Лтд.	Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EP2766020A4 (en) *	2011-10-12	2015-04-01	Teva Pharma	TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
SG11201404214QA (en)	2012-02-03	2014-08-28	Teva Pharma	USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
JP6215238B2 (ja)	2012-02-16	2017-10-18	テバファーマシューティカルインダストリーズリミティド	Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
US20130259856A1 (en) *	2012-03-27	2013-10-03	Teva Pharmaceutical Industries, Ltd.	Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201347762A (zh) *	2012-05-02	2013-12-01	Teva Pharma	高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途
TW201350467A (zh)	2012-05-08	2013-12-16	Teva Pharma	Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
UY34896A (es) *	2012-07-12	2014-02-28	Teva Pharma	Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
TW201410244A (zh)	2012-08-13	2014-03-16	Teva Pharma	用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
SG11201501874TA (en) *	2012-10-12	2015-05-28	Pharmaceutical Industries Ltd Teva	Laquinimod for reducing thalamic damage in multiple sclerosis
CA2890194A1 (en)	2012-11-07	2014-05-15	Teva Pharmaceutical Industries Ltd.	Amine salts of laquinimod
EA201591507A1 (ru) *	2013-02-15	2015-12-30	Тева Фармасьютикал Индастриз Лтд.	Лечение рассеянного склероза лахинимодом
MX2015010967A (es)	2013-03-14	2015-10-26	Teva Pharma	Formulaciones transdermicas de laquinimod.
US20160046582A1 (en)	2013-03-14	2016-02-18	Teva Pharmaceutical Industries Ltd.	Crystals of laquinimod sodium and improved process for the manufacture thereof
CN105848653A (zh) *	2013-09-27	2016-08-10	梯瓦制药工业有限公司	用于治疗多发性硬化症的拉喹莫德联合治疗
SG11201608674UA (en) *	2014-04-29	2016-11-29	Teva Pharma	Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2016094516A1 (en) *	2014-12-10	2016-06-16	Teva Pharmaceutical Industries Ltd.	Treatment of multiple sclerosis with combination of laquinimod and a statin
WO2017048457A1 (en) *	2015-09-18	2017-03-23	Teva Pharmaceuticals Industries Ltd.	Combination of laquinimod and pridopidine to treat multiple sclerosis
WO2017120355A1 (en) *	2016-01-06	2017-07-13	Teva Pharmaceutical Industries Ltd.	Dihydroquinolines and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6696407B1 (en) *	1997-03-21	2004-02-24	The Regents Of The University Of California	Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) *	1998-04-27	2000-06-20	Active Biotech Ab	Quinoline derivatives
US6133285A (en) *	1998-07-15	2000-10-17	Active Biotech Ab	Quinoline derivatives
US6121287A (en) *	1998-07-15	2000-09-19	Active Biotech Ab	Quinoline derivatives
WO2002007757A2 (en) *	2000-07-21	2002-01-31	Lue Tom F	Prevention and treatment of sexual arousal disorders
US6307050B1 (en) *	2000-08-29	2001-10-23	R. T. Alamo Venture I Llc	Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) *	2002-06-12	2005-04-05	Active Biotech Ab	Process for the manufacture of quinoline derivatives
US7560557B2 (en) *	2002-06-12	2009-07-14	Active Biotech Ag	Process for the manufacture of quinoline derivatives
US20070292461A1 (en) *	2003-08-04	2007-12-20	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
PE20050232A1 (es) *	2003-06-25	2005-04-01	Elan Pharm Inc	Metodo y composiciones para tratar la artritis reumatoide
US8795693B2 (en) *	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
SE0400235D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
US8314124B2 (en) *	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
JP2007531735A (ja) *	2004-04-01	2007-11-08	エランファーマシューティカルズ，インコーポレイテッド	ステロイド節約剤および該節約剤を使用する方法
US20080085484A1 (en) *	2004-07-20	2008-04-10	Henrik Tormquist	Lighter Extension Device
EP1796710A4 (en) *	2004-09-02	2010-05-26	Teva Pharma	THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
AU2006344395B2 (en) *	2005-10-13	2013-05-02	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive diseases
RS53666B1 (en) *	2005-10-19	2015-04-30	Teva Pharmaceutical Industries Ltd	CRYSTALS OF SODIUM LAKVINIMOD AND THE PROCESS FOR OBTAINING THEM
CN101346353B (zh) *	2005-10-26	2012-01-11	默克雪兰诺有限公司	磺酰胺衍生物及其在调节金属蛋白酶中的用途
US20080108641A1 (en) *	2006-02-08	2008-05-08	Ajami Alfred M	Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) *	2006-02-14	2013-02-05	Noxxon Pharma Ag	MCP-1 binding nucleic acids and use thereof
WO2007100763A2 (en) *	2006-02-28	2007-09-07	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
CA2641513C (en) *	2006-02-28	2021-09-21	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with natalizumab
KR20080104343A (ko) *	2006-03-03	2008-12-02	엘란 파마슈티칼스, 인크.	나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
US9399061B2 (en) *	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
DK2035001T3 (da) *	2006-06-12	2012-02-27	Teva Pharma	Stabile laquinimod-tilberedninger
US20080118553A1 (en) *	2006-06-12	2008-05-22	Anton Frenkel	Tannate salt form of polypeptide mixtures, their preparation and use
EP2056818B1 (en) *	2006-08-11	2011-05-25	The Johns Hopkins University	Compositions and methods for neuroprotection
CN101848712B (zh) *	2007-07-11	2013-07-24	美迪诺亚公司	用异丁地特治疗渐进性神经变性疾病
SI2234485T1 (sl) *	2007-12-20	2014-03-31	Teva Pharmaceutical Industries Ltd.	Stabilni lakvinimodni pripravki
WO2010028015A2 (en) *	2008-09-03	2010-03-11	Auspex Pharmaceuticals, Inc	2-oxo-1,2-dihydro-quinoline modulators of immune function
MX337614B (es) *	2010-03-03	2016-03-10	Teva Pharma	Tratamiento de lupus nefritis usando laquinimod.
SG183513A1 (en) *	2010-03-03	2012-09-27	Teva Pharma	Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
ES2601819T3 (es) *	2010-03-03	2017-02-16	Teva Pharmaceutical Industries Ltd.	Tratamiento de la artritis lúpica usando laquinimod
MX2013000332A (es) *	2010-07-09	2013-02-26	Teva Pharma	5-cloro-4-hidroxi-1-metil-2-oxo-n-fenil-1,2-dihidroquinolina-3-ca rboxamida, sales y usos de la misma.
CN102984939A (zh) *	2010-07-09	2013-03-20	泰华制药工业有限公司	氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途

2010
- 2010-06-18 ES ES10789873.6T patent/ES2548999T3/es active Active
- 2010-06-18 KR KR1020127001253A patent/KR20120037477A/ko active Application Filing
- 2010-06-18 EP EP15178731.4A patent/EP3028572A1/en not_active Withdrawn
- 2010-06-18 JP JP2012516065A patent/JP2012530701A/ja not_active Withdrawn
- 2010-06-18 HU HUE10789873A patent/HUE026406T2/en unknown
- 2010-06-18 MX MX2011013902A patent/MX2011013902A/es active IP Right Grant
- 2010-06-18 ME MEP-2015-169A patent/ME02282B/me unknown
- 2010-06-18 EP EP10789873.6A patent/EP2442651B1/en active Active
- 2010-06-18 BR BR112012000568A patent/BR112012000568A2/pt not_active IP Right Cessation
- 2010-06-18 PT PT107898736T patent/PT2442651E/pt unknown
- 2010-06-18 WO PCT/US2010/001759 patent/WO2010147665A1/en active Application Filing
- 2010-06-18 SG SG10201403397TA patent/SG10201403397TA/en unknown
- 2010-06-18 CN CN201710171011.XA patent/CN107308162A/zh active Pending
- 2010-06-18 DK DK10789873.6T patent/DK2442651T3/en active
- 2010-06-18 CN CN2010800272294A patent/CN102802415A/zh active Pending
- 2010-06-18 EA EA201270041A patent/EA201270041A1/ru unknown
- 2010-06-18 AU AU2010260455A patent/AU2010260455A1/en not_active Abandoned
- 2010-06-18 RS RS20150645A patent/RS54328B1/en unknown
- 2010-06-18 SI SI201031018T patent/SI2442651T1/sl unknown
- 2010-06-18 SG SG2011092483A patent/SG176840A1/en unknown
- 2010-06-18 US US12/803,121 patent/US20100322900A1/en not_active Abandoned
- 2010-06-18 NZ NZ597378A patent/NZ597378A/en not_active IP Right Cessation
- 2010-06-18 PL PL10789873T patent/PL2442651T3/pl unknown
- 2010-06-18 KR KR1020177026329A patent/KR20170109091A/ko not_active Application Discontinuation
2011
- 2011-12-06 IL IL216780A patent/IL216780A0/en unknown
2012
- 2012-01-03 ZA ZA2012/00029A patent/ZA201200029B/en unknown
- 2012-10-11 HK HK12110013.8A patent/HK1169563A1/xx not_active IP Right Cessation
- 2012-12-12 US US13/712,398 patent/US20130272996A1/en not_active Abandoned
2013
- 2013-12-20 US US14/137,778 patent/US20140105850A1/en not_active Abandoned
2014
- 2014-12-25 JP JP2014263274A patent/JP2015107981A/ja not_active Withdrawn
2015
- 2015-03-02 US US14/635,837 patent/US20150164880A1/en not_active Abandoned
- 2015-09-18 HR HRP20150988TT patent/HRP20150988T1/hr unknown
- 2015-09-30 CY CY20151100869T patent/CY1116727T1/el unknown
- 2015-10-23 SM SM201500262T patent/SMT201500262B/it unknown
- 2015-12-04 US US14/959,845 patent/US20160082001A1/en not_active Abandoned
2016
- 2016-06-01 JP JP2016110233A patent/JP2016199555A/ja active Pending
- 2016-08-16 AU AU2016216586A patent/AU2016216586A1/en not_active Abandoned
- 2016-11-28 US US15/362,535 patent/US20170128435A1/en not_active Abandoned
2017
- 2017-06-06 IL IL252699A patent/IL252699A0/en unknown
- 2017-08-10 JP JP2017155343A patent/JP2018021045A/ja not_active Withdrawn
- 2017-09-11 US US15/701,157 patent/US20180042916A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL252699A0 (en)	2017-07-31
MX2011013902A (es)	2012-02-23
CN102802415A (zh)	2012-11-28
KR20120037477A (ko)	2012-04-19
SG176840A1 (en)	2012-02-28
ME02282B (me)	2016-02-20
JP2015107981A (ja)	2015-06-11
PT2442651E (pt)	2015-10-22
HK1169563A1 (en)	2013-02-01
EP2442651B1 (en)	2015-07-29
ES2548999T3 (es)	2015-10-22
PL2442651T3 (pl)	2015-12-31
US20130272996A1 (en)	2013-10-17
EP2442651A1 (en)	2012-04-25
HRP20150988T1 (hr)	2015-11-20
EP2442651A4 (en)	2012-10-31
EP3028572A1 (en)	2016-06-08
AU2010260455A1 (en)	2012-02-02
JP2016199555A (ja)	2016-12-01
CY1116727T1 (el)	2017-03-15
HUE026406T2 (en)	2016-06-28
US20140105850A1 (en)	2014-04-17
JP2018021045A (ja)	2018-02-08
NZ597378A (en)	2014-08-29
AU2016216586A1 (en)	2016-09-01
KR20170109091A (ko)	2017-09-27
US20160082001A1 (en)	2016-03-24
RS54328B1 (en)	2016-02-29
EA201270041A1 (ru)	2012-06-29
DK2442651T3 (en)	2015-09-21
SG10201403397TA (en)	2014-10-30
CN107308162A (zh)	2017-11-03
US20180042916A1 (en)	2018-02-15
US20100322900A1 (en)	2010-12-23
IL216780A0 (en)	2012-02-29
US20150164880A1 (en)	2015-06-18
ZA201200029B (en)	2013-03-27
JP2012530701A (ja)	2012-12-06
BR112012000568A2 (pt)	2015-10-06
WO2010147665A1 (en)	2010-12-23
US20170128435A1 (en)	2017-05-11
SMT201500262B (it)	2016-01-08

Publication	Publication Date	Title
IL252699A0 (en)	2017-07-31	Use of lequinimod to treat multiple sclerosis
ZA201304280B (en)	2014-08-27	Treatment of jak2-mediated conditions
EP2467372A4 (en)	2013-01-09	TREATMENT OF BDNF ASSOCIATED DISEASES WITH LAQUINIMOD
ZA201301601B (en)	2018-12-19	Treatment of diseases
ZA201401217B (en)	2015-08-26	Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
EP2613786A4 (en)	2013-10-23	TREATMENT OF DISEASES
GB0919097D0 (en)	2009-12-16	Treatment of hard surfaces
GB0915515D0 (en)	2009-10-07	Treatment of vasculoproliferative conditions
EP2464227A4 (en)	2013-02-20	COMPOUNDS AND METHODS OF USE
SG2014014724A (en)	2014-07-30	METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
GB201018147D0 (en)	2010-12-08	Method of treatment
IL206491A0 (en)	2010-12-30	Treatment of produce
IL256026A (en)	2018-01-31	Treatment methods
IL225896A0 (en)	2013-06-27	Treatment of mecp-2 related disorders
GB201003920D0 (en)	2010-04-21	Method of treatment
PT2460509T (pt)	2018-02-13	Composição para tratamento de verrugas
EP2585103A4 (en)	2013-09-25	METHOD OF TREATMENT
EP2440238A4 (en)	2013-01-16	Methods of Treatment
GB201013139D0 (en)	2010-09-22	An improved bed and bath
GB201008694D0 (en)	2010-07-07	An improved bed and bath
GB201002500D0 (en)	2010-03-31	Treatment of burns
HU1000688D0 (en)	2011-02-28	Use of trifluoro-phal
GB201014736D0 (en)	2010-10-20	Treatment of hepatitis C
GB201009194D0 (en)	2010-07-14	Treatment of pain
GB201003917D0 (en)	2010-04-21	Method of treatment